All In Biotech

Drug Trial Radar · NCT03104699

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

A Phase 1/2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

211

Actual

Start

Apr 11, 2017

Primary completion

Jun 15, 2022

Study completion Jun 15, 2022

Sponsor

Lead sponsor
Agenus Inc.Industry
Sponsor type
Industry
First posted
Apr 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part trial: a Phase 1, open-label, dose-escalation study in participants with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in participants with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.

Conditions

  • Advanced Cancer
  • Cervical Cancer

Interventions

  • AGEN2034Drug

    Anti-programmed cell death protein-1 (PD-1) Monoclonal Antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for BalstilimabTime frame: 21 days
  2. Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 3 years
  3. Phase 2: Objective Response Rate (ORR) as Determined by an Independent Endpoint Review Committee (IERC)Time frame: Up to 3 years

Locations

44 sites in 9 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • City of Hope

    Duarte, California

  • University of Southern California - Keck School of Medicine

    Los Angeles, California

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Florida Cancer Specialists & Research Institute

    Sarasota, Florida

  • Augusta Oncology

    Augusta, Georgia

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • The University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Swedish Medical Center-Cherry Hill Campus

    Seattle, Washington

  • Pindara Private Hospital

    Benowa, Queensland, Australia

  • Calvary North Adelaide Hospital

    North Adelaide, South Australia, Australia

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto

    São José do Rio Preto, Brazil

  • IMIP

    Recife, Pernambuco, Brazil

  • Instituto Nacional de Câncer

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Hospital de Caridade de Ijuí

    Ijuí, Rio Grande do Sul, Brazil

  • Hospital Mãe de Deus

    Porto Alegre, Rio Grande do Sul, Brazil

  • Instituto do Cancer do Estado de São Paulo

    São Paulo, São Paulo, Brazil

  • Hospital Amaral Carvalho

    São Paulo, São Paulo, Brazil

  • Centro Oncológico del Norte

    Antofagasta, AN, Chile

  • Centro De Investigación Del Cancer James Lind

    Temuco, AR, Chile

  • Fundación Arturo López Pérez

    Santiago, RM, Chile

  • Bradford Hill

    Santiago, RM, Chile

  • East-Tallinn Central Hospital

    Tallinn, Estonia

  • North Estonia Medical Centre Foundation

    Tallinn, Estonia

  • Institut Bergonié

    Bordeaux, France

  • Centre Léon Bérard

    Lyon, France

  • L'Institut Paoli - Calmettes

    Marseille, France

  • CHU Hôpital de la Timone

    Marseille, France

  • Centre Antoine-Lacassagne

    Nice, France

  • Hôpital Cochin

    Paris, France

  • Groupe Hospitalier Diaconesses Croix Saint-Simon - Hopital de la Croix Saint-Simon

    Paris, France

  • Clinique Armoricaine de Radiologie

    Plérin, France

  • Institute de Cancerologie de l'Ouest (ICO) - René Gauducheau

    Saint-Herblain, France

  • Institut Claudius Regaud

    Toulouse, France

  • Gustave Roussy

    Villejuif, France

  • Szpital Swietego Rafala w Krakowie

    Krakow, Lesser Poland Voivodeship, Poland

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.